What was the main driver behind the significant increase in net income?

The substantial increase in net income was primarily driven by a significant reduction in litigation charges, especially those related to Average Wholesale Price (AWP) litigation, compared to the prior year's periods. Additionally, growth in the Distribution Solutions segment and a gain on a business combination also contributed positively to the improved net income.

How did McKesson's share repurchase program impact financial results?

McKesson's share repurchase program, including an accelerated share repurchase initiated in March 2012, resulted in a reduction of outstanding shares. This reduction positively impacted diluted Earnings Per Share (EPS), as the same net income was spread across fewer shares.

Are there any significant legal or contingent liabilities that investors should be aware of?

Yes, McKesson is subject to various legal proceedings, most notably the ongoing Average Wholesale Price (AWP) litigation and related claims. While litigation charges were lower in this reporting period compared to the prior year, the company has a reserve for estimated probable losses, and the ultimate outcome and cost of these matters remain uncertain and could materially impact future financial results.

What is the outlook for McKesson's revenues, given the slight decrease in the current quarter?

While revenues saw a slight decrease of 1% in the second quarter, they were largely stable for the first six months, with a 1% increase year-over-year. The company attributes this to a mix of factors including price deflation from brand-to-generic drug conversions, but also market growth, increased drug utilization, and price increases. Management expects its operating cash flow, financial assets, and access to capital to be sufficient for its future needs.

MCK 10-Q Quarterly Report Q2 FY2013 — Revenue, Net Income, EPS

Summary

McKesson Corporation reported solid financial results for the second quarter and first six months of fiscal year 2013. Net income saw a substantial increase, rising by 35% year-over-year for the quarter and 34% for the six-month period, translating to a significant improvement in diluted Earnings Per Share (EPS). This performance was driven by growth in the Distribution Solutions segment and a notable reduction in litigation charges compared to the prior year, which had a substantial impact on profitability. The company also benefited from a gain on a business combination during the first half of the fiscal year. Revenues remained relatively stable, showing a slight decrease of 1% for the quarter but a 1% increase for the six-month period, reflecting a mix of offsetting factors including price deflation in the pharmaceutical market and overall market growth. The company continued its strategic initiatives, including significant share repurchases which contributed positively to EPS. McKesson also made progress in managing its working capital and maintained a strong liquidity position, with sufficient operating cash flow and access to credit facilities to fund its operations and capital requirements. While revenues showed resilience, the company is navigating a dynamic market environment characterized by factors such as generic drug conversions and ongoing legal proceedings, although the impact of these legal matters appears to be moderating compared to the previous year.

Financial Highlights

51 data points

Beta

Revenue

$29.75B

0.1% Gross Margin

Net Income

$401.00M

0.0% Net Margin

EPS (Diluted)

$1.67

Total Assets

$32.97B

Cash & Equivalents

$2.83B

Free Cash Flow

$973.00M

Financial Statements

Beta

Revenue	$29.75B
Cost of Revenue	$28.07B
Gross Profit	$1.68B
Operating Expenses	$1.08B
Operating Income	$606.00M
Net Income	$401.00M
EPS (Basic)	$1.70
EPS (Diluted)	$1.67
Shares Outstanding (Basic)	236.00M
Shares Outstanding (Diluted)	240.00M

Key Highlights

1Net income increased by 35% to $401 million for the quarter and 34% to $781 million for the six months ended September 30, 2012, compared to the prior year periods.
2Diluted Earnings Per Share (EPS) significantly improved, rising 42% to $1.67 for the quarter and 41% to $3.25 for the six months, partly due to share repurchases.
3Revenues showed stability, with a slight 1% decrease for the quarter ($29.85 billion) and a 1% increase for the six months ($60.65 billion), indicating a resilient top line.
4Litigation charges, particularly related to Average Wholesale Price (AWP) litigation, decreased substantially, contributing positively to operating income and net income.
5The company completed a gain on business combination of $81 million (pre-tax) recognized in the first half of the fiscal year, boosting overall profitability.
6McKesson continued its aggressive share repurchase program, authorizing an additional $700 million in April 2012, which helps reduce the share count and enhance EPS.
7Liquidity remains strong, with cash and cash equivalents of $2.83 billion and sufficient operating cash flow and credit facilities to meet financial obligations.

MCKESSON CORP Quarterly Report for Q2 Ended Sep 30, 2012

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions